D3

For the approximately 2.4 million children and adolescents living with HIV today, managing health is a lifelong commitment that has traditionally relied on a daily three-drug regimen. While adults have recently benefited from simpler two-drug treatments,

The D3 trial is excited to announce that it has successfully completed recruitment in the trial at an exceptional speed. D3 is looking to see if a new tablet, a combination of two anti-HIV medicines,

A new trial opened in May, aiming to find out if children and young people living with HIV can take two anti-HIV medicines instead of three. The trial has already recruited 57 participants in Uganda and Thailand.